<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01024192</url>
  </required_header>
  <id_info>
    <org_study_id>ZOLPI_L_04134</org_study_id>
    <nct_id>NCT01024192</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Assessment of ZOlpidem (Stilnox CR) in Patients With Chronic insomNIA</brief_title>
  <official_title>Efficacy and Safety Assessment of ZOlpidem (Stilnox CR) Administered on as Needed Basis in Patients With Chronic insomNIA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary Objective:

      To evaluate the efficacy and safety of the use of Stilnox CR in Mexican patients with chronic
      insomnia at the prescription conditions of daily practice

      Secondary Objective:

      To evaluate the satisfaction of the patient with chronic insomnia with Stilnox CR over an as
      needed basis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of the Clinical Global Impression (CGI) score</measure>
    <time_frame>At day 84 (visit 5)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Illness severity and average change during the study</measure>
    <time_frame>At day 1 (baseline), day 14 (visit 2), day 28 (visit 3), day 56 (visit 4) and day 84 (visit 5)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pittsburgh Sleep Quality Index (PSQI) score</measure>
    <time_frame>At day 1 (baseline), day 28 (visit 3), day 56 (visit 4) and day 84 (visit 5)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction questionnaire</measure>
    <time_frame>At day 84 (visit 5)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety evaluation via Adverse events reported</measure>
    <time_frame>At day 14 (visit 2), day 28 (visit 3), day 56 (visit 4) and day 84 (visit 5)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">135</enrollment>
  <condition>Sleep Disorders</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zolpidem 12.5mg tablet at bed time during 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZOLPIDEM SL800750</intervention_name>
    <description>Pharmaceutical form: Zopidem 12.5 mg tablets
Route of administration: Oral
Dose regimen:One tablet at bed time and as needed (the patients choose which night they take the tablet without limit of number of nights)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Primary insomnia diagnosis (difficulty for initiating sleep, or maintaining sleep to wake
        up to early in the morning, or to present a restless sleep) which causes clinically
        significant disturbances in the areas of social, work functioning or other important areas

        Exclusion criteria:

          -  Serious, severe and/or acute respiratory impairment

          -  Severe liver impairment

          -  Hypersensitivity to the formulation components or to some of its active metabolites

          -  Pregnant or breast-feeding women Patients with important associated disorders in SNC
             and specially psychotic disorders

          -  Patients with the probability of using alcoholic beverages concomitantly (as a
             precaution measure)

          -  Chronic use of benzodiazepines

        Moreover, in order to follow the international regulations in terms of the use and handling
        of hypnotic compounds, and to guarantee the appropriate study performance, no patients with
        one or more of the following characteristics should be included:

          -  Patients who cannot comply to follow-up

          -  Patients who have any drug abuse problem

          -  Individuals who work changing night shifts or with pathological snoring

          -  Presence (or suspicion) of sleep apnea, periodical legs movements or restless legs
             syndrome

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Affairs</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Col. Coyoacan</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2009</study_first_submitted>
  <study_first_submitted_qc>November 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2009</study_first_posted>
  <last_update_submitted>October 4, 2010</last_update_submitted>
  <last_update_submitted_qc>October 4, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2010</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Wake Disorders</mesh_term>
    <mesh_term>Parasomnias</mesh_term>
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zolpidem</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

